semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  PCOS Impaired Glucose Tolerance Infertility Vietnamese women with polycystic ovarian syndrome diagnosed followed by Rotterdam (2003) having indications for infertility treatments  Endocrinal abnormalities including thyroid-stimulating hormone (TSH) >5mIU/mL, serum prolactin (PRL) >30ng/mL and any other concomitant endocrinopathy such as a history of hypothyroidism, Cushing's syndrome, premature ovarian insufficiency and late-onset or non-classic congenital adrenal hyperplasia will be excluded Women who were already diagnosed as diabetes by endocrinologists
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Health Knowledge, Attitudes, Practice the household has a newly married couple (married in the last 3 months) a living mother-in-law both the woman and man being over the age of 18  Under 18 not recently married
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hand Osteoarthritis History of hand OA for at least 3 months before enrolment and use of a NASID for ≥ 1 episode of pain; 2. Reported an average possible overall finger joints pain intensity in the dominant hand over the past 48 hours of at least 40mm according to a 100-mm visual analog scale (VAS) after 1-week wash-out period of previous OA medications(Patients applying NSAIDs at the screening had to have an increase in pain in the dominant hand of ≥ 20 mm during washout); 3. Posterior-anterior radiographs had to show Kellgren-Lawrence grade 1, 2, or 3 changes in symptomatic joints; 4. Rheumatoid factor and anticyclonic citrullinated peptide were negative in all eligible participants to inflammatory arthritis; 5. Ability to comply with the study protocol, understand the medical information forms as well as having signed informed consent  History or current evidence of secondary OA(due to causes other than a solely degenerative joint disease) or symptomatic OA at additional locations besides the hand(s) requiring treatment, or any painful syndrome of the upper limb which may interfere with evaluation of hand pain; 2. History of inflammatory arthritis(e.g., rheumatoid arthritis (RA), psoriatic arthritis), hemochromatosis, metabolic, or neuropathic arthropathies; 3. History of trauma, dislocation or operation to the hand or arm in the previous 3 months; 4. Hand pain and stiffness due to tissue scarring or tendinitis; 5. Skin damage or serious skin disorders in the hands; 6. Intake of antidepressants, anticonvulsants, vascular or narcotics during the 10 days prior to beginning the study; 7. Oral, intramuscular, intra-articular or intravenous corticosteroids, or hyaluronic acid injection within 3 months preceding enrollment; 8. Serious uncontrolled medical conditions such as cancer, uncontrolled cardiovascular disorder, severe hepatic/renal insufficiency or coagulation disorder; 9. Known allergy, contraindication or intolerance to diclofenac, acetaminophen, or gel components; 10. Known phobic to acupuncture or received acupuncture treatment within 4 weeks prior to enrollment
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Refractory Acute Myeloid Leukemia Relapsed Acute Erythroid Leukemia Salvage Treatment HVA Regimen Patients with rrAML Patients with the age of 18-80 years old  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) Patients with any conditions not suitable for the trial (investigators' decision)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 15.0-75.0,  COVID-19 Fulfill and accept COVID-19 patients confirmed be regular on appointments  COVID-19 suspected clinically Children refuse to participate
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Patients with chronic non-specific low back pain, with symptoms present for at least three months Patients with a pain intensity of at least 50mm (measured by a 0-100 mm Visual Analog Scale)  Serious spinal pathologies (such as fractures, tumors, inflammatory, and infectious diseases) Patients who used local corticosteroids and/or botulin toxin injection for pain relief within the prior 30 days of the beginning of the study Chronic pain diseases as fibromyalgia and diabetic type 1 Neuropathic pain Previous spinal surgery in the past 12 months Cancer patients Pregnancy or breast feeding
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-66.0,  Cytokine Storm Age ≥30 years old Male and female Jordanian ASU students and employees who live in Amman. Informed written consent from the participant prior to the start of the study. a serum 25(OH)D concentration less than 30 ng/mL  Any eligible subject refuses to apply with informed written consent before the start of the study. Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems. Who are receiving vitamin D3 supplements (3 months before the start of the study). Pregnant, Breastfeeding females, Females using hormonal contraceptives
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Familial Mediterranean Fever MEFV Gene Mutation Children 4 years of age or older or adults Having a clinical picture compatible with an FMF and a previous genetic analysis finding at least one mutation of the MEFV gene pathogenic or possibly pathogenic for the FMF group Newly diagnosed or in the process of follow-up (with no time limit or evolutionary criteria) During specific or non-specific treatment of the disease or without treatment For whom a blood test is planned as part of routine care Whose informed non-opposition has been collected (or parental non-opposition in the case of a minor patient)  Person under legal protection or under the protection of justice or any other protective measures Person out of state to express their consent Person in emergency situation, vital or not Known infections with HIV and / or HBV and / or HCV
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  type1diabetes Subject is 20 to 70 years of age at time of screening 2. Subject's weight is between 50 and 120 kg 3. A clinical diagnosis of Type 1 diabetes as determined by the Investigator for a minimum of 36 months prior to enrollment 4. Subject has ongoing use of an insulin pump and rtCGM ≥ 6 months prior to screening 5. Subject has an A1C value ≤ 10.0% demonstrated at the time of enrollment. 6. Subject uses a rapid-acting analogue insulin in his/her pump 7. Patient is willing to undergo all study procedures 8. English proficiency 9. Minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units 1. Female subject who has a positive serum pregnancy screening test, or who plans to become pregnant during the course of the study 2. Subject has unresolved adverse skin condition, or unable to tolerate tape adhesive, in the area of sensor placement or device replacement (e.g., psoriasis, rash, Staphylococcus infection) 3. Subject has a history of hypoglycemic seizure or hypoglycemic coma within the past 12 months 4. Subjects currently taking adjunct therapy with SGLT2-inhibitors, GLP-1 mimetics, Amylin. 5. Subject has a history of seizure disorder unrelated to diabetes within the past 12 months 6. Gastroparesis, uncontrolled thyroid disorder, Addison dis. , Pituitary insufficiency 7. Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), congestive heart failure, ventricular rhythm disturbances, or thromboembolic disease within the past 6 months 8. Subject has a presence of a cardiac pacemaker or any other device that may be sensitive to radio frequency telemetry 9. Subject has any condition, including screening lab values that in the opinion of the Investigator may preclude him/her from participating in the study and completing study related procedures 10. Subject is actively participating in other investigational study (drug or device) 11. Subjects who consume alcohol daily
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Renal Insufficiency, Chronic History of primary glomerulonephritis eGFR between 60 ml/min and 30 ml/min age between 18-65 years old  secondary GMN severe heart failure (NYHA IV) ongoing infectious diseases ongoing neoplasia hepatic diseases COPD inflammatory bowel disease history of stroke history of acute coronary disease less than 3 months pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 35.0-80.0,  Knee Discomfort Joint Pain Consent to the study and to comply with study product Who have a BMI between 18 and 32 kg/m² Who has mild to moderate knee pain for at least 3 months before enrollment (VAS between 40 to 70 on 100mm scale after respecting a washout period depending on the half-life of the excluded medications) Who has radiographic evidence of Kellgren-Lawrence score 0, 1, 2 and 3 in the tibio-femoral compartment of the target knee Who is able to perform the physical performance-based tests and understands all questions from the WOMAC questionnaire Who is willing to refrain from taking any pain reliever (OTC or prescription) and other pharmacological, nutritional agent (e.g. glucosamine), device or therapy (e.g. acupuncture) which may influence the study outcome during the entire trial (other than determined authorized rescue medication) Who is willing to not change dietary habits, level of physical activity (including any heavy physical work with high loading of the knee joints) and body weight  Subjects with any clinically significant levels of the safety parameters at screening Pregnant or lactating females, or wishing to become pregnant during the study Subject with joint pain related to some predisposing conditions that have adversely altered the joint tissues often due to a specific cause Subject with Kellgren-Lawrence grade 4 in the tibio-femoral compartment of the target knee Who has clinically apparent tense effusion of the target knee or other joint Who has/had viscosupplementation in any joint including the target knee or other joint within 6 months prior to screening Who has concomitant inflammatory disease or other condition that affects the joints deemed exclusionary by the Principal Investigator (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc…) Who has symptomatic osteoarthritis of the contralateral knee that is not responsive to paracetamol and requires other therapy Who is taking any treatment/supplementation which may interfere with study conduct and interpretation of study results (4-weeks washout, e.g. glucosamine, chondroitin, corticosteroids) except calcium and vitamin D supplements Who is under any medical condition deemed exclusionary by the Principal Investigator
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Diabetes Mellitus, Type 2 Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent Body mass index between 21.0 kg/m^2 and 29.9 kg/m^2 (both inclusive) Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator  Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening Use of tobacco and nicotine products, defined as any of the below:1) Smoking more than 5 cigarettes or the equivalent per day.2) Not willing to refrain from smoking and use of nicotine substitute products during the inpatient periods Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator History (as declared by participant) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by participant) Presence or history (as declared by participant) of pancreatitis (acute or chronic)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 55.0-80.0,  Locomotive Syndrome Age >60 years 2. Both genders 3. Greater than 16 score on Geriatric Locomotive Function Scale (GLFS) 4. Complaints related to legs and spine without disability in walking or going out. 5. Score of less than 45 in Berg Balance Scale. 6. Some difficulty in walking due to locomotive organ dysfunction. 7. Good communication and ability to perform activities of Short physical performance battery protocol  Persons with severe co-morbid conditins 2. Stroke 3. Cardiac failure 4. Cognitive impairment 5. Alzheimer's disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Liposarcoma CRC Prostate Cancer Breast Neoplasms Adenocarcinoma of Lung Solid Tumors Disease Characteristics Breast Cancer (Part 1A, Part 1B and Part 1C) Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer (2L + with prior CDK 4/6) locally advance or metastatic breast cancer. Participants should have received at least 1 line of SOC, including CDK4/6 inhibitor therapy, or at least 1 line of anti-endocrine therapy in countries without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease Part 1A only: Refractory HR-positive (HR+), Human Epidermal Growth Factor Receptor 2 Positive (HER2+) breast cancer Evaluable lesion (including skin or bone lesion only) Disease Characteristics Part 1A: Tumors other than BC Participants with advanced or metastatic disease Participants with histological or cytological diagnosis of adenocarcinoma of NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests, that is resistant to at least 2 lines of standard systemic therapy for advanced or recurrent disease or for which no standard therapy is available Participants must not be eligible to undergo therapy with curative intent (surgery or radiation therapy with or without chemotherapy General  Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ Major surgery or radiation within 4 weeks prior to study intervention Last anti-cancer treatment within 2 weeks prior to study intervention Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry Pregnant or breastfeeding female participant Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non Specific Vaginitis adult women who already had sexual intercourse diagnosis of non-specific vaginal inflammation by medical examination  microbiologically confirmed bacterial vaginosis treatment with antibiotic therapy according to official protocols and guidelines allergies to one of the plant species included in the vaginal test diabetes mellitus pregnancy lactation immunodeficiency disorder severe chronic illness previous radiotherapy, chemotherapy and biological therapy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease(CKD) Hyperphosphatemia Blood Pressure Age >18 Estimated glomerular filtration rate (eGFR) 20-45 ml/min Medically stable for two months prior to study start Written and verbally information is given Read, speak and understands Danish Written consent  Treatment with phosphate binders Metabolic disorders that requires specific dietary regulation Treatment with chemotherapy within the past 6 months Pregnancy and breastfeeding Food allergies Vegans
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Pain, Postoperative Obesity Thoracic Paravertebral Blocks Ultrasound Performance American Society of Anesthesiologists (ASA) physical status of 1-3 Capable of consenting Capable of understanding the instructions for using the NRS pain scores Capable of replying the questions Lack of contraindications to regional anesthesia (allergy to a LA, local infection, and coagulopathy) and especially TPVB Absence of mental/psychiatric disorders Absence of chronic analgesic/opioid use Absence of alcohol/illicit drug use  Patient refusal of RA/TPVB performance American Society of Anesthesiologists (ASA) physical status of 4 Not capable of consenting Not capable of understanding the instructions for using the NRS pain scores Not capable of replying the questions Contraindications to regional anesthesia (allergy to a LA, local infection, and coagulopathy) and especially TPVB Presence of mental/psychiatric disorders Presence of chronic analgesic/opioid use Presence of alcohol/illicit drug use